Share Price:

APNASPENAspen Pharmacare Hldgs11581-61 (-0.52%)

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Aspen concludes agreement to manufacture and make available an Aspen-branded COVID-19 vaccine (Aspenovax) throughout Africa

Stephen Saad, Aspen Group Chief Executive

β€œWith the conclusion of this agreement, our vision for Africa’s own vaccine has become a reality,” said Stephen Saad, Aspen Group Chief Executive.

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below: